MASQUELIER’s® Original OPCs found to delay aging of blood vessels

INC | 3 December 2008

New research shows a potential novel biological activity of oligomeric proanthocyanidins. As present in MASQUELIER’s® Original OPCs, this complex...

Read full article  MASQUELIER’s® Original OPCs found to delay aging of blood vessels
New research shows a potential novel biological activity of oligomeric proanthocyanidins. As present in MASQUELIER’s® Original OPCs, this complex phytonutrient was shown to delay aging in human vascular endothelial cells. The effect on what is technically called ‘senescence’ is possibly due to reducing DNA damage and oxidative stress.

The results of the research project, A Potential Role for Oligomeric Proanthocyanidins (OPCs) in delaying Senescence in Endothelial Cells, were presented by International Nutrition Company’s Dr. Geetha Achanta at the 15th Annual Meeting of the Society for Free Radical Biology and Medicine, held from 19 to 23 November in Indianapolis. The study was performed under supervision of Dr. Jan Andries Post at the Center for Cellular Architecture and Dynamics Department of the University of Utrecht in the Netherlands.

The MASQUELIER’s® OPCs used in this study has been shown in our previous investigations to exhibit strong antioxidant activity. The findings from the current study suggest a novel biological activity for the product: delaying endothelial cell senescence. We are currently attempting to further elucidate the mechanisms by which the product delays endothelial cell senescence, which would provide a firm basis for testing its potential application in maintaining cardiovascular health.”

Arteries are lined on the inner side by a single, continuous layer of cells called endothelial cells. These endothelial cells have been found in laboratory experiments to undergo a finite number of cell divisions, after which growth halts. This phenomenon is called replicative cellular senescence and is suggested to occur in vivo with ageing of blood vessels. Senescence in endothelial cells also occurs upon exposure to oxidative stress, a phenomenon referred to as stress-induced premature senescence (SIPS).

In the study, MASQUELIER’s® Original OPCs, a well characterized dietary supplement from Vitis vinifera seeds rich in specific oligomeric proanthocyanidins, was found to markedly delay the onset of replicative senescence in human endothelial cells cultured in the laboratory, using several established tests for assessing senescence. Additionally, the ingredient was also found to effectively delay SIPS caused by exposure to rotenone, a chemical substance that is known to generate oxidative stress.

Interestingly, the ability of MASQUELIER’s® OPCs to delay senescence was associated with a decrease in the levels of a marker of DNA damage and DNA terminal ends (gamma-H2AX), suggesting that the possible molecular mechanism by which OPCs delay senescence in endothelial cells is through reduction in DNA damage. This hypothesis is supported by observations made in other research studies, showing that extent of DNA damage and levels of gamma-H2AX increase as cells progress to senescence. Reducing levels of DNA damage could therefore delay cellular senescence.

In previous investigations performed at Utrecht University it has been shown to significantly protect human LDL from oxidation, further supporting a potential for this product in maintaining cardiovascular health.

MASQUELIER’s® OPCs produce vascular benefits in smokers.

INC | 18 january 2012

“Integrating all measured effects into a global, so-called vascular health index revealed a significant improvement of overall vascular health by...

Read full article  MASQUELIER’s® OPCs produce vascular benefits in smokers.
“Integrating all measured effects into a global, so-called vascular health index revealed a significant improvement of overall vascular health by MASQUELIER’s® Original OPCs compared to placebo.”

That’s the outcome of a study performed by the Department of Toxicology of Maastricht University, published in the December issue of PLOS One. The research team led by Dr. Antje Weseler faced the challenge of studying the cardiovascular effects in healthy people. This is one of the requirements developed by the European Food Safety Agency (EFSA) in examining health claims. “Food scientists,” so write Weseler and colleagues, “are facing the challenge to prove the clinical efficacy of nutrients that modulate human physiology in a subtle and non-specific manner. In drug research, where the one-target-one-hit concept is imperative, randomized clinical trials with a well-defined single endpoint are the gold standard of efficacy testing. However, a single endpoint neither sufficiently reflects the multifarious nature of nutrients’ functions in humans nor the complexity of pathomechanisms underlying virtually all diseases. Our study pioneered the implementation of a pragmatic solution for this problem: Carefully select a representative panel of markers that reflect the major relevant pathological aberrations and integrate all measured effects into a global health index.”

In order to study the beneficial health effects of dietary supplements in a healthy population, one must elevate the levels of the of the relevant parameters by exerting a certain stress. Still, the disturbances should be mild, so that no pharmacological intervention is required. The smokers recruited for the trial fulfilled these criteria adequately. Using a daily dosage of MASQUELIER’s® OPCs in the range that fits normal consumption of a varied and healthy diet, the new integrative multi-biomarker approach proved to be a sensitive and therefore powerful strategy to unveil the multifarious benefit of an 8 week supplementation. This research project confirms the vast amount of scientific work performed since professor Jack Masquelier first isolated the active principles of MASQUELIER's® Original OPCs. For health conscious consumers, the postive results take the product from maintaining their vascular health to reducing the risk of vascular disease.

The study showed a significant decrease in serum total cholesterol and LDL. Additionally, after 8 weeks of supplementation, the ratio of glutathione to glutathione disulphide in erythrocytes rose from baseline by 22% in the supplemented subjects. The researchers also observed that MASQUELIER’s® OPCs exerts anti-inflammatory effects in blood towards ex vivo added bacterial endotoxin and significantly reduces expression of inflammatory genes in leukocytes. Conversely, alterations in biomarkers such as platelet aggregation, plasma levels of nitric oxide surrogates, endothelin-1, C-reactive protein, and prostaglandin F2alpha, did not reach statistical significance. However, integrating all measured effects into a global vascular health index and taking into account that the trial was performed with healthy subjects, it was concluded that MASQUELIER’s® OPCs produces a significant improvement of overall vascular health compared to placebo.